标签归档：microbix

MICROBIX 代理

发表于由

MICROBIX 代理

简要描述：MICROBIX 代理，MICROBIX ，MICROBIX 代理，中国代理，MICROBIX 上海代理，MICROBIX 北京代理，MICROBIX 国内代理，MICROBIX 大陆代理，MICROBIX 代理，MICROBIX 大陆代理，MICROBIX 代理

详细介绍

产品咨询

MICROBIX 代理，MICROBIX ，MICROBIX  代理，MICROBIX 代理中国代理，MICROBIX 上海代理，MICROBIX 北京代理，MICROBIX 国内代理，MICROBIX 大陆代理，MICROBIX 代理，MICROBIX 大陆代理，MICROBIX 代理
加拿大MICROBIX公司，提供的传染病产品，如TORCH，衣原体，流感抗原。使用技术在biotherapeutic药物，疫苗和传染病诊断和生产urokinase、腺病毒、retroviral和其他抗原和抗体。

Name & Catalogue No. Description Applications
Chlamydia trachomatis  PT-12-M1 (1 mL)
  • Chlamydia trachomatis in stabilizing buffer
  •  Positive control in molecular diagnostic tests (PCR)
  • Proficiency Testing
Neisseria gonorrhoeae  PT-17-M1 (1 mL)
  • Neisseria gonorrhoeae in stabilizing buffer
  •  Positive control in molecular diagnostic tests (PCR)
  • Proficiency Testing
C. trachomatis/N. gonorrhoeaePT-12-M2 (1 mL)
  • Chlamydia trachomatis and Neisseria gonorrhoeae in stabilizing buffer
  •  Positive control in molecular diagnostic tests (PCR)
  • Proficiency Testing
Group B StreptococcusPT-19-M1 (1 mL)
  • Group B Streptococcus bacterial in stabilizing buffer
  •  Positive control in molecular diagnostic tests (PCR)
  • Proficiency Testing
Negative Control with Human DNAPT-99-M1
  • Human DNA in stabilizing buffer with no exogenous DNA
  •  Negative control in molecular diagnostic tests (PCR)
  • Proficiency Testing

上海金畔生物科技有限公司MICROBIX 代理，竭诚为您提供MICROBIX 代理产品，产品*，货到付款，实验无忧！                                                      

上海金畔生物科技有限公司

Microbix特色产品

发表于由

Microbix是为生物制药研究实验室，诊断和世界各地的学术机构提供的生物制品与服务。生物制品的旨在为生物技术提供的行业标准。Microbix提供zui高质量的动物和人血清，血浆，纯化蛋白和抗体，Microbix的产品在市场上具有竞争力的价格优势。Microbix生产当今世界上的质量和纯度的白蛋白，丙种球蛋白和IgG抗体。
关于Microbix，Quidel.
Microbix是我们的姊妹公司，其目标和使命是被*为研究行业的人血，人体血液成分和生物液体的供应商。为了实现这一目标，我们的政策是制定和实现质量标准，使我们能够提供特定的材料，以满足您的需求。


Microbix EL-05-15

产品名称：RUBELLA BR2S抗原

目录编号：EL-05-15

储存：将此抗原制剂冷冻储存在-70°

C至–100 o

C.应重复冷冻和解冻

避免。

危害：该产品已被灭活。没有任何检测方法可以保证产品不具有传染性。所有产品

应该像潜在的传染性一样处理。适用于

处理该产品时应使用生物试剂。

菌株：HPV-77

培养于：Vero细胞，一种来自非洲绿猴肾脏的已建立的细胞系。

缓冲液：NTE缓冲液（氯化钠、TRIS和EDTA）

病原体描述：风疹引起儿童和成人的轻度皮疹，称为德国麻疹。有

经常是咽炎和颈部淋巴结肿大。感染经常发生在儿童时期

许多感染是无症状的，并发症是罕见的。然而，前16名妇女的感染情况

怀孕几周会导致意气相投







Microbix特色产品


大鼠补体冻干

山羊抗人（CRP）

无菌过滤的小鼠血清低内毒素

食蟹猴血清白蛋白冻干粉

 

Microbix部分产品信息如下：
E60-0001 SLR66-00005
Equine IgG solution >= 97% purity, 1gm Rabbit IgG, 500mg
E60-0010 SLR66-0001
Equine IgG solution >= 97% purity, 10gm Rabbit IgG, 1gm
E60-0100 SLR66-0100
Equine IgG solution >= 97% purity, 100gm Rabbit IgG, 100gm
E60-1000 B60-0001
Equine IgG solution >= 97% purity, 1KG Bovine IgG solution >= 97% purity, 1gm
B60-0010 SLD66-0100
Bovine IgG solution >= 97% purity, 10gm Donkey IgG, 100gm
B60-0100 SLD66-00005
Bovine IgG solution >= 97% purity, 100gm Donkey IgG, 500mg
B60-1000 SLD66-0001
Bovine IgG solution >= 97% purity, 1KG Donkey IgG, 1gm
CA60-0100 CA60-0500
Canine IgG solution >= 97% purity, 100mg Canine IgG solution >= 97% purity, 500mg
CA60-1000 C60-0001
Canine IgG solution >= 97% purity, 1gm Chicken IgY solution >= 97% purity, 1gm
C60-0010 C60-0100
Chicken IgY solution >= 97% purity, 10gm Chicken IgY solution >= 97% purity, 100gm
R60-0010 R60-0001
Rabbit IgG solution >= 97% purity, 10gm Rabbit IgG solution >= 97% purity, 1gm

Microbix代理

发表于由

Microbix代理

简要描述：Microbix代理，Microbix中国代理，Microbix上海代理，Microbix代理，Microbix
Microbix专业代理-上海金畔生物科技有限公司，具体产品信息欢迎电询

详细介绍

产品咨询

Microbix代理，Microbix中国代理，Microbix上海代理，Microbix代理，Microbix
Microbix专业代理-上海金畔生物科技有限公司，具体产品信息欢迎电询

加拿大公司，提供的传染病产品，如TORCH，衣原体，流感抗原。使用技术在biotherapeutic药物，疫苗和传染病诊断和生产urokinase、腺病毒、retroviral和其他抗原和抗体。
www.microbix.com/

 

上海金畔生物科技有限公司
实验试剂一站式采购服务商
1：强大的进口辐射能力，血清、抗体、耗材、大部分限制进口品等。
2：产品种类齐全，经营超过700多个品牌，基本涵盖所有生物实验试剂耗材。
3：提供加急服务，货品一般1-2周到货。
4：富有竞争力的价格优势，绝大部分价格有优势。
5：多年积累良好的信誉，大部分客户提供货到付款服务。客户包括清华、北大、交大、复旦、中山等100多所高校，ROCHE，阿斯利康、国药、fisher等药企。
6：我们还是Santa,Advanced Biotechnologies Inc,Athens Research & Technology,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. FormuMax Scientific,Inc, Genebridege, Glycotope Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,omicronbio, Polysciences,prospecbi, QA-BIO,quickzyme,RESEARCH DIETS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等几十家国外公司代理。
7：我们还是invitrogen,qiagen,Microbixam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等*批发，欢迎合作。

Microbix产品列表

发表于由

Microbix产品列表

简要描述：加拿大生物技术公司Microbix Biosystems

详细介绍

产品咨询

—加拿大生物技术公司Microbix Biosystems（MBX.TO: 行情）周二表示，将与湖南生物医药集团联手建设亚洲规模zui大的流感疫苗生产基地。

 

 

Microbix称，已与湖南生物医药集团成立合作企业，共同建设和运营位于长沙市附近两亿美元的疫苗生产基地。

 

 

 

这将是*三大疫苗生产基地。2013年全面投产後，该基地每年将能够生产超过1亿剂的季节流感疫苗，以及高达3亿剂的一种可预防流感大流行病毒的疫苗，包括甲流病毒。预计工程将于2010年初启动。

 

 

 

Microbix董事长兼*执行官William Gastle向路透表示：“我们将解决中国一个尚未被满足的医疗需求，一些国家疫苗产能不足，无法满足国内人口的疫苗需求，中国就是其中之一。”

EL-15-02
Adenovirus, Grade 2
1 ml 
EL-01-02  Cytomegalovirus, Grade 2 1 ml 
EL-22-02  Dengue Type 2  1 ml 
EL-16-03 Epstein Barr Virus, Cell Extract 1 ml 
EL-16-06  EBV Viral Capsid Ag, Purified 1 ml
EL-25-01 Hepatitis A, Grade 2 1 ml
EL-02-02 Herpes Simplex 1, Grade 2  1 ml
EL-23-02 Herpes Simplex 2, Grade 2 1 ml
EL-13-02 Influenza A, Grade 2 1 ml
EL-13-AD Influenza A Nucleoprotein *NEW* 20 ug
EL-14-03  Influenza B, Grade 2 1 ml
EL-04-02 Measles, Grade 2 1 ml
EL-06-02 Mumps, Grade 2 1 ml
EL-08-02 Parainfluenza 1, Grade 2 1 ml
EL-09-02 Parainfluenza 2, Grade 2 1 ml
EL-10-02 Parainfluenza 3, Grade 2 1 ml
EL-35-02 Rotavirus 1 ml
EL-07-02 Respiratory Syncytial Virus, Grade 2 1 ml
EL-07-AB Respiratory Syncytial Virus. Purified *NEW* 1 mg
EL-05-13 Rubella K0S Concentrate 1 ml
EL-05-10 Rubella K1S 1 ml
EL-05-11 Rubella K2S 1 mg
EL-03-02 Varicella-Zoster, Grade 2 1 ml
EL-11-02
 

Mycoplasma pneumoniae, Grade 2

 1 ml
EL-12-02  Chlamydia trachomatis, Grade 2  1 ml
EL-46-02 Chlamydia pneumoniae  1 ml
 

PD-01-60

 pΔE1sp1A, pΔE1sp1B, pFG140 and pJM17 Kit A
PD-01-61 pAB26, pAB27, pFG140 and pFG173 Kit B
PD-01-62 pΔE1sp1A, pΔE1sp1B, pXC1, pABS.4, pFG140, pBHG10, pBHG11 Kit C
PD-01-64 pDC311, pDC312, pDC315, pDC316, pBHGloxΔE1,3Cre, pFG140 
PD-01-65 pDC511, pDC512, pDC515, pDC516, pBHGfrtΔE1,3FLP, and pFG140
PD-01-67 pDC411, pDC412, pDC415, pDC416, pBHG10, pBHGE3 and pFG140
PD-01-66 AdCreM2, AdfloxLacZ1 and Adfloxluc
PD-01-68 pDC315（io）, pDC316（io）, pBHGloxΔE1,3Cre, pFG140, 293IQ Cells
PD-01-69 pDC515（io）, pDC516（io）, pBHGfrtΔE1,3FLP, pFG140, 293IQ Cells
 

PD-01-01

 pΔE1sp1A
PD-01-02 pΔE1sp1B
PD-01-03 pXC1
PD-01-04 PABS.4
PD-01-05 pFG140
PD-01-06 pJM17
PD-01-07 pAB26
PD-01-08 pAB27
PD-01-09 pFG173
PD-01-10 PBHG10
PD-01-11 PBHG11
PD-01-12 PBHGE3
PD-01-13 pCA3
PD-01-14 pCA4
PD-01-15 pCA13
PD-01-16 pCA14
PD-01-17 pCA17
PD-01-18 pCA18
PD-01-19 PBHG9
PD-01-20 PHCMVsp1LacZ
PD-01-21 pMH4
PD-01-22 pMH5
PD-01-25 pDC311
PD-01-26 pDC312
PD-01-27 pDC315
PD-01-28 pDC316
PD-01-29 pDC411
PD-01-30 pDC412
PD-01-31 pDC415
PD-01-32 pDC416
PD-01-33 pDC511
PD-01-34 pDC512
PD-01-35 pDC515
PD-01-36 pDC516
PD-01-37 pBHGfrtΔE1FLP
PD-01-38 pBHGfrtΔE1,3FLP
PD-01-39 pBHGloxΔE1Cre
PD-01-40 pBHGloxΔE1,3Cre
PD-01-41 pMH5（I）
PD-01-42 AdCre1
PD-01-54 AdCreM2
PD-01-44 AdfloxLacZ1
PD-01-45 Adfloxluc
PD-01-46 PDC315（io）
PD-01-47 PDC316（io）
PD-01-48 PDC515（io）
PD-01-49 PDC516（io）
PD-01-53 Adeno Helper Virus H14
 

PD-02-01

 293 Low Passage Cells
PD-02-02 293 N3S Suspension Cells
PD-02-03 293 E4pIX Cells
PD-02-04 293IQ Cells
PD-02-08 293 Cre4 Cells

Microbix

发表于由

Microbix代理

简要描述：Microbix代理，Microbix中国代理，Microbix上海代理，Microbix代理，Microbix
Microbix专业代理-上海金畔生物科技有限公司，具体产品信息欢迎电询

详细介绍

产品咨询

Microbix代理，Microbix中国代理，Microbix上海代理，Microbix代理，Microbix
Microbix专业代理-上海金畔生物科技有限公司，具体产品信息欢迎电询

加拿大公司，提供的传染病产品，如TORCH，衣原体，流感抗原。使用技术在biotherapeutic药物，疫苗和传染病诊断和生产urokinase、腺病毒、retroviral和其他抗原和抗体。
www.microbix.com/

Microbix Biosystems Inc. develops biological products and technologies. The Company was founded in 1988 as a producer of Infectious Disease Antigens, primarily for the diagnostics market. The Company invests in the virology business to build capacity and develop new products to address emerging market opportunities, while enhancing manufacturing and laboratory capabilities and technologies. Building on expertise in virology and protein biochemistry, the Company developed a pipeline of selected biological technologies including VIRUSMAX (Influenza Virus Yield Enhancement Technology), LumiSort? (Semen Sexing Technology) and the thrombolytic drug, Kinlytic? (Urokinase). Funded by income from the antigen business, the pipeline products take aim at large market opportunities. With Microbix’ core competencies in the Infectious Disease Antigen business, including cell culture, molecular biology, and a GMP quality system, the pipeline products build on Microbix’ strength. Additional funding for research and development, when required, is raised by way of equity and debt offerings.

The Company operates out of two facilities: the infectious disease antigen manufacturing facility located at 265 Watline Avenue, Mississauga, Ontario; and a leased facility at 115 Skyway Avenue, Toronto, wher administration offices are located.

LumiSort?

LumiSort? is next generation instrument based (cytometric) technology that will improve the yield and quality of sexed semen while increasing the speed of sex-sorting by an order of magnitude over methods used in the livestock industry today. It incorporates a novel and innovative instrument design to address fundamental problems with the existing commercial sex selection technology, while providing Microbix with a strong and well differentiated inlectual property advantage in the industry.

LumiSort? technology emerged from Microbix’ research focus in semen sexing initiated in 2005, a program founded to establish a deeper understanding of the biomolecular composition of sperm cells, and focused on the question of delivering high quality sexed semen.

Urokinase

Urokinase (previously marketed under the trade names Kinlytic?, and Abbokinase?) is a natural human protein that stimulates the human body’s blood clot-dissolving processes. Urokinase is an injectable drug and is approved in Canada and the U.S. for clinical use as a thrombolytic agent for the treatment of pulmonary embolism and coronary occlusion. The drug’s originator, Abbott Laboratories, also received approval to market Urokinase in Canada for treatment of pulmonary embolism and the clearance of blocked biomedical catheters.

In September 2008, Microbix acquired all of the assets relating to the approval and sale of Urokinase in the United States, including the New Drug Application (NDA 21-846) filed by Abbott Laboratories with the U.S. Food and Drug Administration (FDA). Microbix originally identified Urokinase as a product for the Company to develop in order to become established in the biological drug business in the U.S. The product, a protein derived from large scale tissue culture, is a good fit with Microbix core competencies in cell culture, process scale-up, and protein biochemistry.

Microbix intends to serve the Urokinase market through existing FDA and more recently Health Canada approvals, leveraging opinion leader relationships, and formulary listings US hospitals. The Company plans to utilize our established, approved raw materials banks and Microbix’ expertise in cell culture production to proceed with the validation of Microbix’ Urokinase production facility, which will serve existing and new markets. The company will pursue inlectual property for new indications, particularly in ophthalmology and oncology.

Microbix intends to re-introduce Urokinase together with a partner bringing the financial and market resources to complement Microbix’ technical and infrastructure capabilities for Urokinase manufacture.

Virology 

The Virology business develops, manufactures and distributes infectious disease antigens for the medical diagnostic and vaccine research industries. The Company has commercialized over 60 products derived from infectious pathogens cultured and processed at its facilities.

VIRUSMAX?

VIRUSMAX technology is a proprietary process for recovery of more virus from influenza virus-infected chick embryos (eggs) to enhance influenza vaccine production. Virus associated with granular and fibrous debris in the allantoic fluid can be disassociated from the debris and recovered, thereby increasing yield. These increases enhance the productivity of the influenza vaccine manufacturing processes and decrease the time required to produce vaccine in response to emergent viral strains.

Patents have been granted in the U.S., Canada, Europe, India, Italy, Australia, China, Argentina, Mexico and Japan.

Microbix signed its first agreement to establish a manufacturing joint venture agreement in China to build and manage a new flu vaccine manufacturing facility.

上海金畔生物科技有限公司

实验试剂一站式采购服务商
1：强大的进口辐射能力，血清、抗体、耗材、大部分限制进口品等。
2：产品种类齐全，经营超过700多个品牌，基本涵盖所有生物实验试剂耗材。
3：提供加急服务，货品一般1-2周到货。
4：富有竞争力的价格优势，绝大部分价格有优势。
5：多年积累良好的信誉，大部分客户提供货到付款服务。客户包括清华、北大、交大、复旦、中山等100多所高校，ROCHE，阿斯利康、国药、fisher等药企。
6：我们还是Santa,Advanced Biotechnologies Inc,Athens Research & Technology,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. FormuMax Scientific,Inc, Genebridege, Glycotope Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,omicronbio, Polysciences,prospecbi, QA-BIO,quickzyme,RESEARCH DIETS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等几十家国外公司代理。
7：我们还是invitrogen,qiagen,Microbixam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等*批发，欢迎合作。